Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
Mené sur 626 patients atteints d'un cancer de la prostate hormonosensible et de stade métastatique (durée médiane : 21,1 mois), cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité de l'ajout du pembrolizumab à l'enzalutamide combiné à un traitement anti-androgénique
Background: Despite treatment advances, most patients with metastatic hormone-sensitive prostate cancer (mHSPC) experience disease progression to castration-resistant disease within 5 years. The placebo-controlled, double-blind, phase III KEYNOTE-991 study evaluated the efficacy and safety of adding pembrolizumab to enzalutamide and androgen deprivation therapy (ADT) in participants with mHSPC.
Patients and methods: Eligible participants were aged ≥18 years with next-generation hormonal agent‒naive mHSPC. Participants were randomly assigned (1:1) to receive intravenous pembrolizumab 200 mg or placebo every 3 weeks for ≤35 cycles, with oral enzalutamide 160 mg and continuous ADT. Primary end points were radiographic progression-free survival (rPFS) and overall survival. Safety was a secondary end point.
Results: Between March 2, 2020, and August 9, 2021, 626 participants were randomly assigned to pembrolizumab plus enzalutamide and ADT and 625 participants to placebo plus enzalutamide and ADT. At the first interim analysis, the median follow-up was 21.1 months (range, 14.8-32.0 months). rPFS was not superior with pembrolizumab versus placebo (median not reached in both arms; hazard ratio, 1.20 [95% confidence interval (CI), 0.96 to 1.49]; P = 0.9467). Median overall survival was not reached in either arm (hazard ratio, 1.16 [95% CI, 0.88 to 1.53]; not formally statistically tested per the multiplicity strategy). Grade ≥3 adverse events (AEs) and serious AEs were reported in 61.9% versus 38.1% and 40.3% versus 23.2% of participants in the pembrolizumab versus the placebo arm, respectively. Any-grade rash occurred at a higher frequency with pembrolizumab (25.1%) versus placebo (9.3%).
Conclusion: KEYNOTE-991 did not meet its primary end point and was stopped for futility. The addition of pembrolizumab to enzalutamide and ADT was associated with higher frequencies of grade ≥3 AEs and serious AEs than with placebo. Rash was identified as an additional safety signal with pembrolizumab plus enzalutamide and ADT.
Annals of Oncology , résumé, 2025